Browsing Tag
siRNA therapy
2 posts
From metabolism to genetics: Can ARO-PNPLA3 change the MASH playbook
Can ARO-PNPLA3 reshape MASH drug development? Discover how Madrigal Pharmaceuticals, Inc. is expanding into precision therapies.
Lilly’s lepodisiran shows 94% reduction in lipoprotein(a), offering hope for cardiovascular risk management
Lilly’s lepodisiran slashed lipoprotein(a) by 94% in a Phase 2 trial. See how this breakthrough could change cardiovascular disease treatment.